Frontiers in oncology · 2026
The aMAP score improves discrimination of prognostic models in hepatocellular carcinoma after radiofrequency ablation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fan Luchang, Zhang Yiyan, Ding Jianmin, Zhou Yan, Li Jun, Wu Qiong, Cheng Shuqin, Wang Fengmei, Jing Xiang
Аннотация
PURPOSE: The aMAP score has proven a reliable model for predicting the risk of hepatocellular carcinoma (HCC) development in patients with various types of hepatitis, but its value in predicting recurrence in HCC patients after radiofrequency ablation (RFA) remains unclear. This study aims to assess the utility of the aMAP score for predicting recurrence in HCC patients after RFA.
METHODS: The retrospective analysis included 350 firstly diagnosed HCC patients who underwent RFA. Survival analysis was performed using Kaplan-Meier curves with the log-rank test. Cox regression analysis was conducted to assess the prognostic value of aMAP score. The Fine-Gray method was adopted for sensitivity analysis. Subgroup analyses verified the consistency of the aMAP score's predictive value. C-index, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were used to evaluate its incremental predictive value.
RESULTS: Among 350 patients undergoing RFA, a total of 197 (56.3%) patients had a low aMAP score (≤ 63.55), and 153 patients (43.7%) had a high aMAP score (> 63.55). Patients with low aMAP scores exhibited significantly longer recurrence-free survival (RFS) (p = 0.016). Multivariate analysis confirmed that the aMAP score is an independent prognostic factor for RFS (HR = 1.40, p = 0.028). Furthermore, when incorporated into a tumor-related characteristics model (tumor number and size of largest tumor), the aMAP score provided significant incremental value in predicting RFS (IDI 2.6%, p = 0.036; NRI 15.9%, p = 0.036).
CONCLUSIONS: The aMAP score is a potentially predictor for HCC patients undergoing RFA. Incorporation of the aMAP score into the prediction model improved its predictive accuracy.
METHODS: The retrospective analysis included 350 firstly diagnosed HCC patients who underwent RFA. Survival analysis was performed using Kaplan-Meier curves with the log-rank test. Cox regression analysis was conducted to assess the prognostic value of aMAP score. The Fine-Gray method was adopted for sensitivity analysis. Subgroup analyses verified the consistency of the aMAP score's predictive value. C-index, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were used to evaluate its incremental predictive value.
RESULTS: Among 350 patients undergoing RFA, a total of 197 (56.3%) patients had a low aMAP score (≤ 63.55), and 153 patients (43.7%) had a high aMAP score (> 63.55). Patients with low aMAP scores exhibited significantly longer recurrence-free survival (RFS) (p = 0.016). Multivariate analysis confirmed that the aMAP score is an independent prognostic factor for RFS (HR = 1.40, p = 0.028). Furthermore, when incorporated into a tumor-related characteristics model (tumor number and size of largest tumor), the aMAP score provided significant incremental value in predicting RFS (IDI 2.6%, p = 0.036; NRI 15.9%, p = 0.036).
CONCLUSIONS: The aMAP score is a potentially predictor for HCC patients undergoing RFA. Incorporation of the aMAP score into the prediction model improved its predictive accuracy.